10.02.2011 • News • Chris Viehbacher • Chris Viehbacher CEO • Sanofi

Sanofi CEO Says Genzyme Offer May Be Extended

Sanofi Aventis Chief Executive Chris Viehbacher said in an interview that the French pharmaceuticals group's offer for Genzyme could be extended for a third time, beyond the Feb. 15 deadline.

Asked by La Tribune newspaper about the deadline, Viehbacher said: "It is a possibility, there are no limits on takeover offers in the United States."

He added: "It is normal to spend time on an operation of $18.5 billion."

Viehbacher's interview is to be published in La Tribune business newspaper on Thursday and was made available late on Wednesday.

Virtual Event

CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Expert Insights

Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.